ArticleOncotarget2019
The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.European radiology · 2022Pooled it
- Theranostics for prostate cancer: A Canadian multidisciplinary expert report.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.European journal of nuclear medicine and molecular imaging · 2026Article
- The diagnostic accuracy of [99mTc]Tc-PSMA SPECT/CT for recurrent prostate cancer based on individual patient attributes.European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [European journal of nuclear medicine and molecular imaging · 2025Article
- Estimating the Optimal Time to Perform a Positron Emission Tomography With Prostate-Specific Membrane Antigen in Prostatectomized Patients, Based on Data From Clinical Practice.Biometrical journal. Biometrische Zeitschrift · 2025Article
- Article
- Preclinical Characterization of theInternational journal of molecular sciences · 2023Article
- Detection Efficacy ofCancers · 2023Article
- Feasibility and Optimal Time Point of [European urology open science · 2022Article
- Article
- Article
- Clinical utility ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings onThe Journal of urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.